Frontera. The APEX in Gene Therapy Development.

Frontera is a leading clinical-stage biotechnology company that seeks to develop the best gene therapy medicines to improve the lives of patients across multiple disease areas.

Frontera's APEX Technology & Manufacturing Platform is an innovative adeno-associated virus (AAV) gene expression system. It includes novel and clinically validated AAV vectors, efficient and fully-integrated CMC processes, and access to early clinical data, making it possible to develop novel gene therapy products with quicker speed-to-market and lower cost.

  • World-class execution – leveraging fully integrated teams – across disease biology, gene therapy vector design, translational sciences, process and analytical development, in-house GMP manufacturing and clinical research.
  • State-of-the-art GMP facilities.
  • World-class and proven team in gene therapy R&D, having been in leading roles or as founders for some of the most successful and innovative gene therapy and gene editing products and companies.
  • Early access to clinical data made possible by Frontera’s unique scientific model.

Pipeline

Product development in gene therapy has historically focused on a limited number of rare monogenic disorders. The possibilities for gene therapy, however, are vastly greater. Frontera is realizing this potential with a pipeline that spans across not only orphan diseases, but also in larger patient markets – including Ophthalmology, Hematology, Cardiovascular and Metabolic Diseases.

幻灯片1

World-Class R&D Team

Frontera's elite R&D team is made up of founders and scientific advisors from some of the most successful gene therapy development organizations around the world, bringing together the most advanced thinking in gene therapy, translational research, and biomanufacturing.

Scientific Advisory Board

Scientific Advisory Board

Philip Reilly, Ph.D.

Scientific Advisory Board

Glenn Pierce, Ph.D.

Scientific Advisory Board

Robert Kotin, Ph.D.

Scientific Advisory Board

Fraser Wright, Ph.D.

Scientific Advisory Board

George Church, Ph.D.

Scientific Advisory Board

Jean Bennett, M.D., Ph.D.

Scientific Advisory Board

Mark Kay, M.D., Ph.D.

Scientific Advisory Board

Xandra Breakefield, Ph.D.

Board of Directors

Wei Li, Ph.D.

Chairman, Founding Partner of Creacion Ventures

Carl Gordon, Ph.D.

Managing Partner, OrbiMed Advisors

David Wang, M.D., Ph.D.

Partner, OrbiMed Advisors

Ching Zhu, Ph.D.

Founding Partner of Creacion Ventures

Xinyan Li, Ph.D.

Co-Founder & CEO

Yanling Cao

Partner, Boyu Capital

Jiang Han

Managing Director, Sequoia Capital China

Management Team

The Frontera leadership team has broad experience  from their previous leadership roles in  global pharmaceutical companies as well as innovative biotech startups. The teams’ expertise spans from translational research and development of gene therapy products and biologics, GLP TOX studies, chemistry, manufacturing and Controls (CMC), clinical trial design and management, business development, new drug registration and commercialization.

Management Team

Xinyan Li, Ph.D.

Co-Founder & CEO

Management Team

Jasmine Gao

VP of Clinical Development

Management Team

Robert Lu, Ph.D.

Founder & Sr. VP of Technical Operations

Management Team

Allison Jia

VP of Finance

Investors

OrbiMed.svg
CreacionLogo
boyu-capital_owler_20160227_223607_original
Sequoia-Capital-China

Recent News

Frontera’s Study Report on ” Case Studies of Resolving AAV Aggregation & Removing Empty Vectors ” will be presented in Gene Therapy for Rare Disorders 2024

March 18, 2024

Boston, USA – March 18, 2024 – Frontera Therapeutics, a leading biotechnology company committed to advancing gene therapy drugs to address unmet medical needs worldwide, is delighted to announce its participation in the upcoming 7th Gene Therapy for Rare Disorders 2024 Conference in Boston, USA. Dr. Robert Lu, Senior Vice President of Frontera, has been […]

Read More

Frontera Therapeutics’ FT-002 Achieves Orphan Drug Designation from the U.S. FDA for Inherited Retinal Dystrophies

January 23, 2024

BEDFORD, Mass., and Suzhou, China, January 23, 2024 — Frontera Therapeutics announces that its pioneering AAV gene therapy product, FT-002, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of Inherited Retinal Dystrophies (IRD) caused by RPGR gene variants. About Orphan Drug Designation Orphan Drug Designation, granted […]

Read More

Preliminary Clinical Study Results of Frontera Therapeutics FT-002 Injection Presented at APVRS Congress

December 10, 2023

Hongkong, China, Decemeber 8th, 2023 – Preliminary clinical study results of FT-002, an AAV gene therapy treatment of Frontera Therapeutics, a potential first in class therapy for the treatment of XLRP, were reported at the 16th Asia-Pacific Vitreo-Retina Society, APVRS, 2023). Professor Sui Ruifang from Peking Union Medical College Hospital was invited to participate in […]

Read More

Frontera Therapeutics Initiates Phase II Clinical Trial for FT-001 in Hereditary Retinopathy Treatment

December 5, 2023

Beijing, China, Decemeber 3rd, 2023 – Frontera Therapeutics (Suzhou) Co., Ltd. (hereinafter referred to as Frontera Therapeutics) convened a meeting in Beijing on December 3 to conclude the Phase I clinical study of FT-001, and initiate the Phase II clinical study. The meeting was attended by esteemed clinical experts, including Professor Sui Ruifang, Professor Yu […]

Read More

Frontera Therapeutics announces CDE clearance to initiate clinical trial of a First-in-class gene therapy for the treatment of RPGR-associated X-linked Retinitis Pigmentosa

November 6, 2023

BEDFORD, Mass., and SHANGHAI, China, Nov 6th, 2023 – Frontera Therapeutics (Suzhou) Co., Ltd (referred to as Frontera) announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has given clearance of the Investigational New Drug (IND) application to begin a clinical trial of an innovative gene therapy drug, FT-002, for […]

Read More

The Frontera’s third gene therapy treatment has been approved by CDE for clinical studies

July 14, 2023

BEDFORD, Mass., and SHANGHAI, China, July 12, 2023 – An application for an investigational study in human patients with FT-004, an innovative gene therapy drug independently developed by Frontera Biotechnology (Suzhou) Co., Ltd. (hereinafter referred to as “Frontera Biotechnology”), was approved by the Center for Drug Evaluation (CDE) of China National Medical Products Administration for […]

Read More

A first in China – Frontera Therapeutics Doses First Patient in a Clinical Trial of FT-003 Gene Therapy for the Treatment of DME

June 13, 2023

BEDFORD, Mass., and SHANGHAI, China, June 13th 2023 – Frontera Therapeutics announced another major clinical milestone: FT-003 was successfully dosed for the first patient with Diabetic Macular Edema (DME) in the Ophthalmic Hospital of Tianjin Medical University. This marks the first treatment of gene therapy  for this indication in China. Read the original article Li […]

Read More

Frontera Therapeutics Doses First Patient in a Trial of FT-002 Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa

February 16, 2023

Three of Frontera’s gene therapy product candidates have entered clinical trials since the beginning of 2023 BEDFORD, Mass., and SHANGHAI, China, February 16, 2023 — Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, announced that it […]

Read More

Frontera Therapeutics Doses First Patient in a Clinical Trial of FT-003 Gene Therapy for the Treatment of Wet AMD

February 2, 2023

BEDFORD, Mass., and SHANGHAI, China, February 2, 2023 – Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, announced that it has dosed the first patient in a clinical trial of its innovative gene therapy product, FT-003, […]

Read More

Frontera Therapeutics Doses First Patient in Phase 1 Clinical Trial for Gene Therapy FT-001 for the Treatment of Leber Congenital Amaurosis-2

January 6, 2023

BEDFORD, Mass., and SHANGHAI, China, January 6, 2023 — Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, today announced that it has dosed the first patient in a Phase 1 clinical trial of its lead gene […]

Read More